Evidence map›Paper›PMID 42433233›Full record

ReviewTranslational lung cancer research2026

Current advances in extended resections for non-small cell lung cancer-a narrative review.

Katharina Sinn, Merjem Begic, Mir Alireza Hoda, Clemens Aigner

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Katharina Sinn *Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-3936-2354
Merjem Begic *Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-3488-3118
Mir Alireza HodaDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-7088-8768
Clemens AignerDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-7787-991X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Locally advanced non-small cell lung cancer (NSCLC) encompasses a biologically and anatomically highly heterogenous spectrum. For tumours with infiltration of the chest wall, thoracic inlet, central airways, great vessels, diaphragm or vertebral column, the goal of surgery remains a complete R0 resection, but the boundary between resectable and unresectable disease is fluid and depends on anatomy, nodal burden, response to induction therapy, functional reserve as well as institutional experience. This review summarizes current concepts in extended resection and proposes a practical framework for patient selection. Methods: We performed a narrative review of literature indexed in PubMed, Embase, Scopus and Google Scholar from January 2000 to January 2026. Priority was given to guidelines, expert consensus statements, prospective studies, systematic reviews/meta-analyses, and recent multicentre or large institutional series. Evidence was synthesized narratively with emphasis on resectability, patient selection, operative strategy and oncologic outcomes. Key Content and Findings: Extended resection is defined as anatomical pulmonary resection combined with Conclusions: Extended resection for locally advanced NSCLC should be considered a tailored multidisciplinary strategy rather than a purely technical exercise. The best candidates are those in whom multimodal therapy can provide an R0 resection with acceptable perioperative risk. Future work should focus on refining resectability criteria, incorporating biological response markers to immunotherapy into decision-making, and prospectively evaluating salvage strategies.

Indexed as

borderline resectabilityextended resectionmultidisciplinary team (MDT)multidisciplinary treatmentNon-small cell lung cancer (NSCLC)operability

Identifiers

PMID42433233
PMCPMC13351948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.